| Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data DC Hassane, ML Guzman, C Corbett, X Li, R Abboud, F Young, ... Blood, The Journal of the American Society of Hematology 111 (12), 5654-5662, 2008 | 241 | 2008 |
| Severe cytokine-release syndrome after T cell–replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti–IL-6 therapy is safe and … R Abboud, J Keller, M Slade, JF DiPersio, P Westervelt, MP Rettig, ... Biology of Blood and Marrow Transplantation 22 (10), 1851-1860, 2016 | 158 | 2016 |
| CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+ CS1 expressing CAR-T cells J O’Neal, JK Ritchey, ML Cooper, J Niswonger, L Sofía González, E Street, ... Leukemia 36 (6), 1625-1634, 2022 | 31 | 2022 |
| Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis R Abboud, F Wan, J Mariotti, M Arango, L Castagna, R Romee, ... Bone Marrow Transplantation 56 (11), 2763-2770, 2021 | 29 | 2021 |
| Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality LW Liu, A Yn, F Gao, M Olson, M Crain, R Abboud, P Westervelt, ... Transplantation and Cellular Therapy 28 (8), 510. e1-510. e9, 2022 | 28 | 2022 |
| Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease R Abboud, J Choi, P Ruminski, MA Schroeder, S Kim, CN Abboud, ... Therapeutic Advances in Hematology 11, 2040620720914489, 2020 | 27 | 2020 |
| Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia R Abboud, E Chendamarai, MP Rettig, KM Trinkaus, PA Riedell, ... Haematologica 105 (8), e404, 2020 | 21 | 2020 |
| Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation A Pruitt, F Gao, E De Togni, H Cochran, S Godbole, M Slade, R Abboud Bone Marrow Transplantation 58 (8), 855-862, 2023 | 12 | 2023 |
| Post-transplant cyclophosphamide eliminates disparity in GvHD-free, relapse-free survival and overall survival between 8/8 matched and 7/8 mismatched unrelated donor … JJ Auletta, MM Al Malki, T DeFor, BC Shaffer, M Gooptu, ... Blood 142, 780, 2023 | 9 | 2023 |
| A single-arm, open-label, pilot study of the JAK1 selective inhibitor itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome in T-cell … R Abboud, F Gao, MP Rettig, J Eisele, L Gehrs, N Wallace, C Abboud Sr, ... Blood 138, 100, 2021 | 8 | 2021 |
| A pilot study of CPX-351 (Vyxeos©) for transplant eligible, higher risk patients with myelodysplastic syndrome MA Jacoby, DA Sallman, BL Scott, M Haney, F Wan, JF DiPersio, ... Blood 138, 540, 2021 | 7 | 2021 |
| Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical SCT with post-transplant cyclophosphamide L Eastburg, DA Russler-Germain, R Abboud, P Westervelt, JF DiPersio, ... Blood 134, 4496, 2019 | 5 | 2019 |
| Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation? R Abboud, M Slade, C Abboud, JF DiPersio Leukemia & Lymphoma 62 (3), 749-751, 2021 | 4 | 2021 |
| Phase I study of baricitinib gvhd prophylaxis in HLA-matched, peripheral blood allogeneic hematopoietic cell transplant MA Schroeder, J Choi, H Atluri, J Atkins, M Harding, J Eisele, F Gao, ... Blood 140 (Supplement 1), 1875-1876, 2022 | 3 | 2022 |
| Post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors BC Shaffer, M Gooptu, TE DeFor, M Maiers, J Bolaños-Meade, R Abboud, ... Journal of Clinical Oncology, JCO. 24.00184, 2024 | 2 | 2024 |
| Janus kinase inhibition in the treatment and prevention of graft-versus-host disease E De Togni, O Cole, R Abboud Frontiers in immunology 15, 1304065, 2024 | 2 | 2024 |
| Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models R Abboud, S Kim, K Staser, RG Jayasinghe, S Lim, P Amatya, CC Frye, ... Frontiers in immunology 14, 1264496, 2023 | 2 | 2023 |
| Pretransplant desensitization of donor-specific anti-HLA antibodies with plasmapheresis and immunoglobulin produces equivalent outcomes to patients with no donor specific … HC Cochran, MJ Slade, C Liu, F Gao, S Godbole, A Pruitt, E De Togni, ... Leukemia & Lymphoma, 1-9, 2024 | 1 | 2024 |
| Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor … JJ Auletta, MM Al Malki, TE DeFor, BC Shaffer, M Gooptu, JB Meade, ... Transplantation and Cellular Therapy 30 (2), S24-S25, 2024 | 1 | 2024 |
| Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation R Abboud, MA Schroeder, MP Rettig, F Gao, JK Ritchey, CN Abboud, ... Blood 142, 651, 2023 | 1 | 2023 |
Geoffrey L. UyProfessor of Medicine, Washington University School of Medicine在 wustl.edu 的电子邮件经过验证
